New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

Ads

You May Also Like

Avadel Pharmaceuticals to Report First Quarter 2017 Results

DUBLIN, Ireland, April 17, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it ...

TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting

SAN DIEGO, May 25, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage ...

Great Basin Scientific Announces Restructuring of Convertible Securities

Exchange of securities will eliminate floorless variable-rate convertible securities;provide access to $11.6 million of ...